Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 85. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Multidisciplinary care for amyotrophic lateral sclerosis1048
Correction to Lancet Neurol 2021; 20: 448–59899
Correction to Lancet Neurol 2024; 23: 168–77849
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease726
RAB32 mutation in Parkinson's disease673
Traumatic brain injury research: homogenising heterogeneity580
The predictive value and clinical use of the neurological pupillary index – Authors' reply525
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply480
Increasing diversity in dementia research475
Lessons and future directions for GBA1-targeting therapies454
Correction to Lancet Neurol 2022; 21: 42–52445
New therapies for Pompe disease: are we closer to a cure?413
Dementia diagnosis in the anti-amyloid era375
Implications of the KIWE trial for low-income and lower-middle-income countries369
Correction to Lancet Neurol 2020; 19: 391–401346
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study341
Global burden of stroke: dynamic estimates to inform action337
Correction to Lancet Neurol 2025; 24: 850–65298
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study284
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r265
The East Asian Parkinson Disease Genomics Consortium241
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study239
A biological classification of Huntington's disease: the Integrated Staging System236
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial235
Management of atherosclerotic extracranial carotid artery stenosis234
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study221
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study206
The relevance of social and commercial determinants for neurological health201
Anti-CD19 CAR T cells for refractory myasthenia gravis190
Surrogate endpoints for progressive multifocal leukoencephalopathy185
The prescription of valproate: risk of harm184
Diana Cejas181
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply181
Considering the neurological health needs of LGBTQIA people180
Beyond the modular brain177
Elia M Pestana Knight177
Aspiring to restore arm and hand function after stroke161
Albert Kwaku Akpalu160
A sensitive portrayal of a controversial condition158
A chilly tale of dementia156
A nasal CGRP receptor antagonist for acute migraine therapy155
A study in healing the wounds of trauma153
Trials in intracerebral haemorrhage: a path to success?151
Correction to Lancet Neurol 2023; 22: 812–25150
Delving into the human mind149
Correction to Lancet Neurol 2022; 21: 284–94146
Epilepsy syndromes: an essential piece of the puzzle144
Movement disorders research in 2021: cracking the paradigm134
Development of treatments for Down syndrome134
Gene therapy for X-linked myotubular myopathy: the challenges133
Parkinson's disease is a recognisable and useful diagnostic entity132
From stroke awareness to stroke action awareness122
Amyotrophic lateral sclerosis from genotoxins alone?120
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment119
Global burden of headache disorders: innovations, disparities, and priorities for action118
Safe laboratory management of prions and proteopathic seeds118
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial117
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro117
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment115
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri114
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial113
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases112
Functional or hysterical?110
Cognitive function in people with functional seizures109
Rethinking AI trials in brain health108
A proposal for equity neuroscience108
Changing multiple-sclerosis-induced thoughts and behaviours103
Supporting young carers across neurological disorders102
Learning to be an adult with a disability101
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response101
Multiple sclerosis in 2022: old players, new insights100
Revisiting candesartan: new evidence for an old option in migraine prevention100
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers97
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial95
New results for risdiplam in spinal muscular atrophy94
Expansion of stenting indications in the USA94
Responsible innovation in neurology91
Correction to Lancet Neurol 2024; 23: 110–2290
Better buildings for elderly people to thrive90
The International Brain Initiative: enabling collaborative science89
Jessica Ailani88
Correction to Lancet Neurol 2022; 21: 620–3188
Brain health in the Philippines87
Encephalitis awareness: our ambitious global endeavour86
Neurological infections in 2023: surveillance and prevention85
0.088823795318604